Subscribe to RSS

DOI: 10.1055/s-0045-1812100
Imaging in Uncommon Uterine Malignancies
Authors

Abstract
This review provides a comprehensive overview of the classification and imaging characteristics of uncommon uterine malignancies, guided by the latest World Health Organization classification of female genital tumors (fifth edition, 2020). We discuss the imaging features of rare entities, including leiomyosarcoma, endometrial stromal sarcoma, stromal tumor of uncertain malignant potential, carcinosarcoma, adenosarcoma, perivascular epithelioid cell tumor, and uterine tumors resembling ovarian sex-cord tumors. Although these malignancies often present with nonspecific and overlapping imaging appearances, advances in cross-sectional imaging (particularly magnetic resonance imaging [MRI]) play a critical role in tumor detection, characterization, staging, and treatment planning. Key MRI findings, such as signal intensity patterns, enhancement characteristics, and diffusion-weighted imaging, can help to narrow differential diagnoses and inform management strategies. By emphasizing distinctive imaging features and their clinical relevance, this review aims to enhance diagnostic confidence and multidisciplinary care for patients with these challenging uterine malignancies.
Keywords
uterus - MRI - sarcoma - mesenchymal - malignancy - leiomyosarcoma - leiomyomas - endometrial stromal sarcoma - carcinosarcoma - STUMPPublication History
Article published online:
14 October 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Li Y, Song W, Gao P. et al. Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021. BMC Cancer 2025; 25 (01) 330
- 2 Wu TI, Yen TC, Lai CH. Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol 2011; 25 (06) 681-689
- 3 Santos P, Cunha TM. Uterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol 2015; 21 (01) 4-9
- 4 Hricak H, Tscholakoff D, Heinrichs L. et al. Uterine leiomyomas: correlation of MR, histopathologic findings, and symptoms. Radiology 1986; 158 (02) 385-391
- 5 Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol 2017; 145 (01) 208-216
- 6 Smith J, Zawaideh JP, Sahin H, Freeman S, Bolton H, Addley HC. Differentiating uterine sarcoma from leiomyoma: BET1T2ER Check!. Br J Radiol 2021; 94 (1125) 20201332
- 7 Hartmann KE, Fonnesbeck C, Surawicz T. et al. Management of Uterine Fibroids. Rockville, MD:: Agency for Healthcare Research and Quality (US);; 2017. . Accessed May 4, 2025 at: http://www.ncbi.nlm.nih.gov/books/NBK537742/
- 8 Yang Q, Madueke-Laveaux OS, Cun H. et al. Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy. Cells 2024; 13 (13) 1106
- 9 Sala E, Rockall AG, Freeman SJ, Mitchell DG, Reinhold C. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology 2013; 266 (03) 717-740
- 10 Aviram R, Ochshorn Y, Markovitch O. et al. Uterine sarcomas versus leiomyomas: gray-scale and Doppler sonographic findings. J Clin Ultrasound 2005; 33 (01) 10-13
- 11 Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI. Ann Nucl Med 2008; 22 (06) 505-512
- 12 Hindman N, Kang S, Fournier L. et al. MRI evaluation of uterine masses for risk of leiomyosarcoma: a consensus statement. Radiology 2023; 306 (02) e211658
- 13 Tamai K, Koyama T, Saga T. et al. The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol 2008; 18 (04) 723-730
- 14 Thomassin-Naggara I, Dechoux S, Bonneau C. et al. How to differentiate benign from malignant myometrial tumours using MR imaging. Eur Radiol 2013; 23 (08) 2306-2314
- 15 Bura V, Pintican RM, David RE. et al. MRI findings in-between leiomyoma and leiomyosarcoma: a Rad-Path correlation of degenerated leiomyomas and variants. Br J Radiol 2021; 94 (1125) 20210283
- 16 Shah SH, Jagannathan JP, Krajewski K, O'Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol 2012; 199 (01) 213-223
- 17 Koyama T, Togashi K, Konishi I. et al. MR imaging of endometrial stromal sarcoma: correlation with pathologic findings. AJR Am J Roentgenol 1999; 173 (03) 767-772
- 18 Huang YL, Ueng SH, Chen K. et al. Utility of diffusion-weighted and contrast-enhanced magnetic resonance imaging in diagnosing and differentiating between high- and low-grade uterine endometrial stromal sarcoma. Cancer Imaging 2019; 19 (01) 63
- 19 Furukawa R, Akahane M, Yamada H. et al. Endometrial stromal sarcoma located in the myometrium with a low-intensity rim on T2-weighted images: report of three cases and literature review. J Magn Reson Imaging 2010; 31 (04) 975-979
- 20 Himoto Y, Kido A, Sakata A. et al. Differentiation of uterine low-grade endometrial stromal sarcoma from rare leiomyoma variants by magnetic resonance imaging. Sci Rep 2021; 11 (01) 19124
- 21 Picerno TM, Wasson MN, Gonzalez Rios AR. et al. Morcellation and the incidence of occult uterine malignancy: a dual-institution review. Int J Gynecol Cancer 2016; 26 (01) 149-155
- 22 Gupta M, Laury AL, Nucci MR, Quade BJ. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology 2018; 73 (02) 284-298
- 23 Zhang C, Gao J, Lu S, Zhang Y, Zhu H. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a retrospective study in a single center. Eur J Obstet Gynecol Reprod Biol 2021; 265: 74-79
- 24 Vilos GA, Marks J, Ettler HC, Vilos AG, Prefontaine M, Abu-Rafea B. Uterine smooth muscle tumors of uncertain malignant potential: diagnostic challenges and therapeutic dilemmas. Report of 2 cases and review of the literature. J Minim Invasive Gynecol 2012; 19 (03) 288-295
- 25 Lin G, Yang LY, Huang YT. et al. Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma / smooth muscle tumor with uncertain malignant potential and benign leiomyoma. J Magn Reson Imaging 2016; 43 (02) 333-342
- 26 Cornfeld D, Israel G, Martel M, Weinreb J, Schwartz P, McCarthy S. MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol 2010; 74 (01) 241-249
- 27 Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009; 104 (03) 177-178
- 28 Ravishankar P, Smith DA, Avril S, Kikano E, Ramaiya NH. Uterine carcinosarcoma: a primer for radiologists. Abdom Radiol (NY) 2019; 44 (08) 2874-2885
- 29 Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol 2011; 23 (05) 531-536
- 30 Menczer J. Review of recommended treatment of uterine carcinosarcoma. Curr Treat Options Oncol 2015; 16 (11) 53
- 31 Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 2015; 137 (03) 581-588
- 32 Bharwani N, Newland A, Tunariu N. et al. MRI appearances of uterine malignant mixed müllerian tumors. AJR Am J Roentgenol 2010; 195 (05) 1268-1275
- 33 Yang C, Oh HK, Kim D. Müllerian adenosarcoma arising from rectal endometriosis. Ann Coloproctol 2014; 30 (05) 232-236
- 34 Yao X, Wang W, He Y. Clinicopathological analysis of 22 Müllerian adenosarcomas and the sequencing of DICER1 mutation. Diagn Pathol 2024; 19 (01) 56
- 35 Momeni Boroujeni A, Kertowidjojo E, Wu X. et al. Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors. Mod Pathol 2022; 35 (11) 1684-1694
- 36 Morikawa K, Baba A, Matsushima S. et al. Magnetic resonance imaging features of uterine adenosarcoma: case series and systematic review. Abdom Radiol (NY) 2025; 50 (07) 3313-3326
- 37 McCluggage WG. A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus. Mod Pathol 2016; 29 (Suppl. 01) S78-S91
- 38 Huang YT, Huang YL, Ng KK, Lin G. Current status of magnetic resonance imaging in patients with malignant uterine neoplasms: a review. Korean J Radiol 2019; 20 (01) 18-33
- 39 Lim GSD, Oliva E. The morphologic spectrum of uterine PEC-cell associated tumors in a patient with tuberous sclerosis. Int J Gynecol Pathol 2011; 30 (02) 121-128
- 40 Tirumani SH, Shinagare AB, Hargreaves J. et al. Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors. AJR Am J Roentgenol 2014; 202 (02) 252-258
- 41 Giordano G, Guareschi D, Thai E. Uterine tumor resembling ovarian sex-cord tumor (UTROSCT): a rare polyphenotypic neoplasm. Diagnostics (Basel) 2024; 14 (12) 1271
- 42 Suzuki C, Matsumoto T, Fukunaga M. et al. Uterine tumors resembling ovarian sex-cord tumors producing parathyroid hormone-related protein of the uterine cervix. Pathol Int 2002; 52 (02) 164-168
- 43 Okada S, Uchiyama F, Ohaki Y, Kamoi S, Kawamura T, Kumazaki T. MRI findings of a case of uterine tumor resembling ovarian sex-cord tumors coexisting with endometrial adenoacanthoma. Radiat Med 2001; 19 (03) 151-153
- 44 Calisir C, Inan U, Yavas US, Isiksoy S, Kaya T. Mazabraud's syndrome coexisting with a uterine tumor resembling an ovarian sex cord tumor (UTROSCT): a case report. Korean J Radiol 2007; 8 (05) 438-442
- 45 Levin G, Capella MP, Meyer R, Brezinov Y, Gotlieb WH. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence. Arch Gynecol Obstet 2024; 309 (06) 2381-2386